论文部分内容阅读
目的观察紫杉醇联合表阿霉素治疗晚期乳腺癌的临床疗效和不良反应。方法紫杉醇135 mg/m2,静滴,第1天;表阿霉素50 mg/m2,静注,第2天。21~28 d为一周期,治疗至少2周期评价疗效。结果全组39例中,CR 4例,PR 19例,NC 13例,PD 3例。有效率(CR+PR)59.0%;中位缓解期为8.5个月(4.5~16个月),中位生存期为18个月,2年生存率为42.5%;不良反应主要为白细胞减少、脱发、神经肌肉毒性和胃肠道反应。结论紫杉醇联合表阿霉素治疗晚期乳腺癌有效率高,不良反应可以耐受。
Objective To observe the clinical efficacy and side effects of paclitaxel combined with epirubicin in the treatment of advanced breast cancer. Method paclitaxel 135 mg / m2, intravenous infusion, on the first day; epirubicin 50 mg / m2, intravenous injection, on the second day. 21-28 days for a period of treatment for at least 2 cycles to evaluate the efficacy. Results Among the 39 patients, 4 were CR, 19 were PR, 13 were NC and 3 were PD. (CR + PR) was 59.0%. The median remission was 8.5 months (4.5-16 months). The median survival time was 18 months and the 2-year survival rate was 42.5%. The main adverse reactions were leukopenia, Hair loss, neuromuscular toxicity and gastrointestinal reactions. Conclusion Paclitaxel combined with epirubicin in the treatment of advanced breast cancer has high efficiency and adverse reactions can be tolerated.